Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 3:07 PM
Ignite Modification Date:
2025-12-24 @ 3:07 PM
NCT ID:
NCT05156892
Brief Summary:
The study's purpose is to understand the effects of a new treatment (suba-itraconazole and tamoxifen) in epithelial ovarian cancer.
Who is it for? Patients may be eligible to join this study with ovarian cancer resistant to platinum-based chemotherapy agents
Study Details:
Participants will receive different doses of tamoxifen and suba-itraconazole to determine the optimal combination dose.
Participants will be seen by the investigators once a week for the first 3 weeks and then once every 4 weeks. Participant will be reviewed by a clinician and undergo regular blood tests, cardiac monitoring and imaging assessments.
Detailed Description:
A phase 1/2 study of Suba-itraconazole and Tamoxifen in platinum resistant ovarian carcinoma
Study:
NCT05156892
Study Brief:
Protocol Section:
NCT05156892